$1.45 Billion is the total value of NEA Management Company, LLC's 53 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ARCELLX INC | $146,201,522 | -0.5% | 4,745,262 | 0.0% | 10.11% | +22.3% | ||
VRNA | VERONA PHARMA PLCsponsered ads | $112,141,840 | -23.2% | 5,584,753 | 0.0% | 7.75% | -5.5% | |
MIRM | MIRUM PHARMACEUTICALS INC | $100,553,557 | +23.2% | 4,186,243 | 0.0% | 6.95% | +51.5% | |
IONQ INC | $89,881,198 | +78.3% | 14,614,829 | 0.0% | 6.21% | +119.3% | ||
CRSP | CRISPR THERAPEUTICS AGnamen akt | $71,818,636 | +11.3% | 1,587,854 | 0.0% | 4.96% | +36.9% | |
GLUE | MONTE ROSA THERAPEUTICS INC | $59,923,001 | +2.4% | 7,692,298 | 0.0% | 4.14% | +25.9% | |
BERKSHIRE GREY INC | $52,692,572 | +128.5% | 38,183,023 | 0.0% | 3.64% | +181.0% | ||
BHG | BRIGHT HEALTH GROUP INC | $48,059,242 | -66.1% | 218,153,623 | 0.0% | 3.32% | -58.3% | |
SVRA | SAVARA INC | $47,068,965 | +25.8% | 24,137,931 | 0.0% | 3.25% | +54.7% | |
AUPH | AURINIA PHARMACEUTICALS INC | $43,509,381 | +153.7% | 3,969,834 | 0.0% | 3.01% | +212.0% | |
DM | DESKTOP METAL INC | $33,117,532 | +69.1% | 14,398,927 | 0.0% | 2.29% | +108.1% | |
RPHM | RENEO PHARMACEUTICALS INC | $28,617,254 | +156.7% | 4,785,494 | 0.0% | 1.98% | +215.5% | |
ALLK | ALLAKOS INC | $27,355,307 | -47.1% | 6,147,260 | 0.0% | 1.89% | -35.0% | |
ZEROFOX HLDGS INC | $26,380,029 | -67.4% | 18,068,513 | 0.0% | 1.82% | -59.9% | ||
CVRX | CVRX INC | $22,093,452 | -49.2% | 2,370,542 | 0.0% | 1.53% | -37.5% | |
ADAP | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $18,616,958 | -25.3% | 17,079,779 | 0.0% | 1.29% | -8.1% | |
BUZZFEED INC | $17,327,298 | +63.9% | 15,333,892 | 0.0% | 1.20% | +101.7% | ||
NEXTNAV INC | $16,623,987 | -30.7% | 8,189,156 | 0.0% | 1.15% | -14.8% | ||
CTIC | CTI BIOPHARMA CORP | $15,479,869 | -30.1% | 3,685,683 | 0.0% | 1.07% | -14.1% | |
INZY | INOZYME PHARMA INC | $13,967,958 | +445.7% | 2,437,689 | 0.0% | 0.97% | +570.8% | |
CELC | CELCUITY INC | $12,812,510 | -26.8% | 1,250,001 | 0.0% | 0.89% | -10.0% | |
NKTX | NKARTA INC | $12,669,173 | -40.7% | 3,568,781 | 0.0% | 0.88% | -27.1% | |
XFOR | X4 PHARMACEUTICALS INC | $10,211,010 | -12.4% | 11,736,793 | 0.0% | 0.71% | +7.8% | |
TUYA | TUYA INCsponsered ads | $9,326,470 | -1.0% | 4,934,640 | 0.0% | 0.64% | +21.7% | |
CSBR | CHAMPIONS ONCOLOGY INC | $6,889,154 | -10.9% | 1,713,720 | 0.0% | 0.48% | +9.7% | |
BDTX | BLACK DIAMOND THERAPEUTICS INC | $6,518,151 | +5.0% | 3,448,757 | 0.0% | 0.45% | +29.2% | |
LXRX | LEXICON PHARMACEUTICALS INC | $5,788,955 | +27.2% | 2,382,286 | 0.0% | 0.40% | +56.2% | |
IVA | INVENTIVA SAads | $4,993,269 | -28.7% | 1,462,586 | 0.0% | 0.34% | -12.4% | |
ACRIVON THERAPEUTICS INC | $4,889,985 | +10.2% | 481,677 | 0.0% | 0.34% | +35.7% | ||
GOSS | GOSSAMER BIO INC | $4,368,932 | -41.9% | 3,467,406 | 0.0% | 0.30% | -28.6% | |
AFMD | AFFIMED NV | $3,300,389 | -39.9% | 4,426,488 | 0.0% | 0.23% | -26.0% | |
SYBX | SYNLOGIC INC | $2,672,690 | -16.8% | 4,228,940 | 0.0% | 0.18% | +2.2% | |
RGLS | REGULUS THERAPEUTICS INC | $1,224,734 | -38.1% | 1,445,114 | 0.0% | 0.08% | -23.4% | |
OBSV | OBSEVA SA | $499,935 | -24.8% | 4,586,563 | 0.0% | 0.04% | -5.4% | |
AKTX | AKARI THERAPEUTICS PLCsponsored adr | $82,159 | -61.3% | 452,167 | 0.0% | 0.01% | -50.0% | |
AIRSPAN NETWORKS HOLDINGS INC*w exp 08/13/2023 | $67 | +9.8% | 69,928 | 0.0% | 0.00% | – | ||
AIRSPAN NETWORKS HOLDINGS INC*w exp 08/13/2023 | $30 | -72.7% | 69,928 | 0.0% | 0.00% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
GLYCOMIMETICS INC | 39 | Q3 2023 | 7.6% |
AURINIA PHARMACEUTICALS INC | 37 | Q3 2023 | 5.0% |
CHAMPIONS ONCOLOGY INC | 33 | Q3 2023 | 1.2% |
LEXICON PHARMACEUTICALS INC | 32 | Q3 2023 | 2.0% |
ADAPTIMMUNE THERAPEUTICS PLC | 31 | Q3 2023 | 9.3% |
TREVENA INC | 31 | Q3 2021 | 3.3% |
AKARI THERAPEUTICS PLC | 31 | Q2 2023 | 0.3% |
ARDELYX INC | 29 | Q3 2021 | 11.9% |
RIGEL PHARMACEUTICALS INC | 29 | Q2 2020 | 0.6% |
EPIZYME INC | 28 | Q1 2020 | 9.6% |
View NEA Management Company, LLC's complete holdings history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-05-15 |
13F-HR | 2024-02-14 |
13F-HR | 2023-11-14 |
13F-HR | 2023-08-11 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-10 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
13F-HR | 2022-05-16 |
13F-HR | 2022-02-14 |
View NEA Management Company, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.